Korean J Med.  2009 Jul;77(1):1-8.

Recent advance in tailored treatment of gastric cancer

Affiliations
  • 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.

Abstract

Even the overall incidence is decreasing and the proportion of early gastric cancer is increasing from the national mass screening program, still gastric cancer is the major issue in Korea. Multimodality approach and the development of novel therapeutic agents enabled us to improve the survival rate of gastric cancer. However, the proper treatment strategy for the subgroups of patients is necessary, which is now categorized based on the clinicopathologic parameters. We need more in-depth information regarding the molecular biology of gastric cancer, and the development of novel targeted biological agents and the biomarkers for the future. Currently, the recent chemotherapeutic agents showed the improved response in advanced gastric cancer. Hence, the basic concept of adjuvant chemotherapy, palliative chemotherapy, neoadjuvant treatment with or without incorporation of radiotherapy become settle down with more evidences from several phase III trials. Especially, after understanding the difference between Asia and Western countries including biology, ethnic difference, operation technology, and the treatment approaches, the qualified, well-designed multinational clinical trials are on-going. Based on the current results, here, I describe the current status of gastric cancer treatment strategy.

Keyword

Gastric cancer; Chemotherapy; Tailored treatment; Biological agent

MeSH Terms

Asia
Biological Agents
Biomarkers
Biology
Chemotherapy, Adjuvant
Humans
Incidence
Korea
Mass Screening
Molecular Biology
Neoadjuvant Therapy
Stomach Neoplasms
Survival Rate
Biological Agents
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr